Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | FOS | P01100 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4692320 | 0.86 | FAAH (0.58) | FAAHMMP2MMP13MMP14NPC1 | |
| SCHEMBL2203443 | 0.86 | MMP2 (0.49) | FAAHMMP2MMP13MMP14NR1H2 | |
| SCHEMBL1779589 | 0.85 | CA9 (0.59) | FAAHMMP2MMP13MMP14NR1H2 | |
| SCHEMBL30130655 | 0.85 | FAAH (0.57) | FAAHMMP2MMP13MMP14NPC1 | |
| SCHEMBL10958938 | 0.82 | FAAH (0.54) | FAAHMMP2MMP13MMP14NR1H2 | |
| SCHEMBL30504042 | 0.82 | FAAH (0.54) | FAAHMMP2MMP13MMP14NR1H2 | |
| SCHEMBL2203114 | 0.81 | RPA1 (0.51) | NPC1RAB9AMAPT | |
| SCHEMBL4504419 | 0.80 | PLA2G10 (0.55) | FAAHNPC1RAB9ACA9SMN1; SMN2 | |
| SCHEMBL15868122 | 0.80 | SMN1; SMN2 (0.45) | FAAHMMP2MMP13MMP14NPC1 | |
| SCHEMBL17375118 | 0.80 | FAAH (0.52) | FAAHMMP2MMP13MMP14NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206136-B2 | Pyrazolyl-based carboxamides I | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206136-B2 | Pyrazolyl-based carboxamides I | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| WO-2014108337-A1 | PYRAZOLYL-BASED CARBOXAMIDES I AS CRAC CHANNEL INHIBITORS | Grünenthal GmbH (DE) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194443-A1 | Pyrazolyl-Based Carboxamides I | Grünenthal GmbH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| EP-1615895-A4 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| EP-1615895-A1 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004092140-A1 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1379511-A1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
| WO-2002083652-A1 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | FAAH 274/4885MMP2 3793/4885MMP13 2206/4885 |
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | TRPV1, TRPA1, TRPV3 | FAAH 596/4885MMP2 2594/4885MMP13 3839/4885 |
| US-20140194443-A1 | Pyrazolyl-Based Carboxamides I | AADAC, HDAC3, NLRP3 | FAAH 1038/4885MMP2 4450/4885MMP13 3001/4885 |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | FAAH 606/4885MMP2 4345/4885MMP13 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.